Terveystalo Oyj (HEL:TTALO)
Finland
· Delayed Price · Currency is EUR | Market Cap | 961.25M |
| Revenue (ttm) | 1.24B |
| Net Income (ttm) | 76.40M |
| Shares Out | 126.81M |
| EPS (ttm) | 0.61 |
| PE Ratio | 12.45 |
| Forward PE | 9.83 |
| Dividend | 0.64 (8.44%) |
| Ex-Dividend Date | Oct 7, 2026 |
| Volume | 267,060 |
| Average Volume | 295,205 |
| Open | 7.58 |
| Previous Close | 7.58 |
| Day's Range | 7.50 - 7.64 |
| 52-Week Range | 7.40 - 12.58 |
| Beta | 0.44 |
| RSI | 22.34 |
| Earnings Date | Apr 24, 2026 |
About Terveystalo Oyj
Terveystalo Oyj provides occupational healthcare services in Finland, Sweden, and Estonia. It operates through three segments: Healthcare Services, Portfolio Businesses, and Sweden. The company offers general practice and specialist medical care, diagnostic, outpatient surgery, dental, and other adjacent services; healthcare outsourcing and staffing services; child welfare services; and oral health, social, ER, well-being, and primary healthcare and specialty care services, as well as imaging and laboratory tests. It also provides remote and di... [Read more]
Financial Performance
In 2025, Terveystalo Oyj's revenue was 1.28 billion, a decrease of -4.56% compared to the previous year's 1.34 billion. Earnings were 92.60 million, an increase of 29.15%.
Financial StatementsNews
Q1 2026 Terveystalo Oyj Earnings Call Transcript
Q1 2026 Terveystalo Oyj Earnings Call Transcript
Terveystalo Oyj Earnings Call Transcript: Q1 2026
Revenue and profitability declined sharply in Q1 2026 amid an exceptionally weak healthcare market, but operational efficiency and digital investments remained strong. Management expects gradual recovery from H2, with full-year EBIT guidance maintained and key growth initiatives underway.
Terveystalo Oyj Earnings Call Transcript: Q4 2025
All-time high profitability and efficiency achieved despite revenue declines and market headwinds. 2026 guidance reflects a wide range due to macro and seasonal uncertainties, with investments in digital transformation and M&A supporting future growth.
Terveystalo Oyj Earnings Call Transcript: Q3 2025
Q3 delivered improved margins and strong cash flow despite a 5% revenue decline, with Sweden and portfolio businesses showing efficiency gains. Guidance for adjusted EBIT is maintained at EUR 155–165 million, and digital investments and M&A activity are set to drive future growth.
Terveystalo Oyj Earnings Call Transcript: Q2 2025
Record Q2 EBIT and margin achieved despite lower revenue, driven by efficiency gains and improved profitability across all segments. Outlook for H2 is positive, supported by the Kela 65 pilot, public sector demand, and ongoing digitalization initiatives.
Terveystalo Oyj Earnings Call Transcript: Q1 2025
Q1 saw strong profitability gains with adjusted EBIT up 20% and EPS up 40% year-over-year, despite a slight revenue decline due to softness in Sweden and outsourcing contract expiries. Guidance for 2025 is reiterated, with growth and margin improvement expected.
Terveystalo Oyj Earnings Call Transcript: Q4 2024
Record financial and quality results in 2024, with strong revenue and EBITDA growth, improved margins, and robust cash flow. Guidance for 2025 targets further margin and EPS growth, supported by ongoing efficiency and technology investments.
Terveystalo Oyj Transcript: CMD 2024
Turnaround has been delivered ahead of schedule, with a structurally stronger, less risky business and a confident shift to balanced, organic growth. Digitalization, integrated care, and targeted investments drive profitability, while new financial targets focus on 10% EPS growth and high dividends.
Terveystalo Oyj Transcript: Jefferies London Healthcare Conference 2024
A leading Nordic healthcare provider reported strong profitability and growth, driven by digital integration, operational improvements, and resilience in a challenging market. Future plans focus on incremental growth, technology investment, and leveraging demographic and funding trends.